Exhibition Dates: September 1-3, 2025
Exhibition Venue: Shenzhen Convention and Exhibition Center (Futian)
Booth Number: 9A02
From September 1 to 3, 2025, the annual global pharmaceutical industry event—CPHI World Pharmaceutical Industry Exhibition (Shenzhen)—will take place at the Shenzhen Convention and Exhibition Center (Futian). Shandong Tianming Pharmaceutical Group Co., Ltd. is fully prepared and will be waiting for your visit at Booth 9A02!
Shandong Tianming Pharmaceutical has always been committed to the research, development, production, and global supply of high-quality active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. At Booth 9A02, you will gain a comprehensive and in-depth understanding of our offerings.
Our product portfolio spans cardiovascular medications, diabetes medications, anticancer medications, antibiotics, and health supplements, among other areas, delivering consistent and reliable quality to meet our customers’ diverse needs.
Whether you are exploring customized cooperation solutions or seeking stable and high-quality supply chain support, our professional team is ready and eager to discuss development opportunities and explore mutually beneficial cooperation with you!
WhatsApp: +176 6371 3557
Email: sunqian0123@gmail.com
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.